ISBER 2020 Apr 14, 2020 20200414 Jan 18, 2020 California, U.S. In April 2020, global leaders and disruptors from the broad spectrum of scientific community will converge in the largest international biobank conference, ISBER 2020, to address the impact of biobanks on science and how the related discoveries are establishing a roadmap to extend our knowledge network. From engaging with vulnerable populations to advances in artificial intelligence, experts at ISBER 2020 will highlight critical advances in biobanking and, for the first time, host a debate to discuss the utilization of samples and data in the modern era. /content/dam/pmiscience/default-fallback-thumbnails/conference/pmi-science-background.png

      ISBER 2020

      Date
      Apr 14, 2020 - Jan 18, 2020
      Location
      California, U.S.
      In April 2020, global leaders and disruptors from the broad spectrum of scientific community will converge in the largest international biobank conference, ISBER 2020, to address the impact of biobanks on science and how the related discoveries are establishing a roadmap to extend our knowledge network. From engaging with vulnerable populations to advances in artificial intelligence, experts at ISBER 2020 will highlight critical advances in biobanking and, for the first time, host a debate to discuss the utilization of samples and data in the modern era.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.